• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Optical/Ophthalmic

Glaukos beats The Street in Q3

November 2, 2022 By Sean Whooley

Glaukos logo

Glaukos (NYSE:GKOS) shares hardly shifted on third-quarter results that came in ahead of the consensus forecast. The Aliso Viejo, California-based ophthalmic implant maker posted losses of $27.6 million in the quarter. That amounts to 58¢ per share on sales of $71.3 million for the three months ended Sept. 30, 2022. Glaukos registered a deep bottom-line […]

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Glaukos

5 top ophthalmic device innovations you need to know

September 27, 2022 By Sean Whooley

Pixabay image of an eye to symbolize ophthalmic device innovations in the medtech medical device industry

Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye. Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic Tagged With: Alcon, bausch&lomb, Clearside Biomedical, Glaukos, Johnson & Johnson, Johnson & Johnson Vision, Second Sight

Phase 3 trial data support Glaukos iDose eye drop alternative

September 7, 2022 By Sean Whooley

Glaukos iDose

Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Pharmaceuticals Tagged With: Glaukos

Second Sight Medical merges with Nano Precision Medical, rebrands as Vivani Medical

August 30, 2022 By Sean Whooley

Second Sight Medical Nano Precision Medical

Second Sight Medical (Nasdaq:EYES) announced today that it completed its merger with Nano Precision Medical and rebranded. In February, the two companies entered into a definitive agreement under which Nano Precision Medical (NPM) would merge with a wholly-owned subsidiary of Second Sight in an all-stock transaction, with NPM as the surviving company under Second Sight’s […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Mergers & Acquisitions, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Nano Precision Medical, Second Sight, Vivani Medical

AbbVie enters partnership with iStar with option to acquire

July 20, 2022 By Sean Whooley

MINIject iSTAR

AbbVie (NYSE:ABBV) announced today that it entered into a strategic alliance with iStar Medical over the MINIject device. The strategic transaction centers around helping to further develop and commercialize iStar’s MINIject minimally invasive glaucoma surgical (MIGS) device. It will also provide AbbVie with a chance to expand its eye care business through an option to […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Implants, Mergers & Acquisitions, Optical/Ophthalmic Tagged With: AbbVie, iSTAR Medical

Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment

May 23, 2022 By Sean Whooley

Kala Pharmaceuticals Alcon Eysuvis

Alcon (NYSE:ACL) announced today that it agreed to acquire Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals. Geneva, Switzerland-based Alcon will pay $60 million upfront to Kala for the dry eye treatment. As part of the agreement, the company will also acquire Kala’s Inveltys corticosteroid for twice-per-day treatment of post-operative inflammation and pain following ocular surgery. […]

Filed Under: Business/Financial News, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Alcon, Kala Pharmaceuticals

Johnson & Johnson Vision wins Fast Company award for drug-eluting contact lens

May 4, 2022 By Sean Whooley

Johnson & Johnson Vision drug eluting contact lens acuvue Theravision_FDA Revised Carton

Johnson & Johnson Vision announced today that it was named a winner of Fast Company’s 2022 World Changing Ideas Awards. The eye health business arm of Johnson & Johnson (NYSE: JNJ) received the award in the “Wellness” category for its Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen). The drug-eluting contact, which provides […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Johnson & Johnson, Johnson & Johnson Vision

Bausch + Lomb, Clearside Biomedical launch Xipere in U.S.

March 28, 2022 By Sean Whooley

Bausch_Health_ Clearside Biomedical

Bausch Health’s (NYSE:BHC) Bausch + Lomb and Clearside Biomedical (Nasdaq:CLSD) launched their Xipere product in the U.S. today. Clearside Biomedical designed the Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for treating macular edema associated with uveitis, a form of eye inflammation. Xipere works with Clearside’s proprietary SCS Microinjector to deliver the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Bausch Health, bausch&lomb, Clearside Biomedical

Johnson & Johnson is bringing the world’s first drug-eluting contact lens to market

March 21, 2022 By Sean Whooley

Johnson & Johnson Vision drug eluting contact lens acuvue Theravision_FDA Revised Carton

Johnson & Johnson has a potential alternative to eye drops with its drug-eluting Acuvue Theravision contact lens. As far back as the early 1960s, researchers toyed with the idea of delivering medication through contact lenses. Johnson & Johnson Vision (NYSE:JNJ) Director of Clinical Science Dr. Brian Pall told Drug Delivery Business News that patents back then […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: janssen, Johnson & Johnson, Johnson & Johnson Vision

FDA approves Johnson & Johnson Vision’s drug-eluting contact lens

March 2, 2022 By Sean Whooley

Johnson & Johnson Vision Acuvue Theravision

Johnson & Johnson Vision announced today that it received FDA approval for its Acuvue Theravision with Ketotifen. The eye health business arm of Johnson & Johnson (NYSE: JNJ) designed Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen) to provide a new wearing experience for contact lens wearers who have allergic eye itch […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: Johnson & Johnson, Johnson & Johnson Vision

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 31
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS